Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis

Background: Individuals with chronic obstructive pulmonary disease (COPD) are at increased risk of cardiovascular diseases, osteoporosis, and muscle wasting. Systemic inflammation may be involved in the pathogenesis of these disorders. A study was undertaken to determine whether systemic inflammation is present in stable COPD. Methods: A systematic review was conducted of studies which reported on the relationship between COPD, forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC), and levels of various systemic inflammatory markers: C-reactive protein (CRP), fibrinogen, leucocytes, tumour necrosis factor-α (TNF-α), and interleukins 6 and 8. Where possible the results were pooled together to produce a summary estimate using a random or fixed effects model. Results: Fourteen original studies were identified. Overall, the standardised mean difference in the CRP level between COPD and control subjects was 0.53 units (95% confidence interval (CI) 0.34 to 0.72). The standardised mean difference in the fibrinogen level was 0.47 units (95% CI 0.29 to 0.65). Circulating leucocytes were also higher in COPD than in control subjects (standardised mean difference 0.44 units (95% CI 0.20 to 0.67)), as were serum TNF-α levels (standardised mean difference 0.59 units (95% CI 0.29 to 0.89)). Conclusions: Reduced lung function is associated with increased levels of systemic inflammatory markers which may have important pathophysiological and therapeutic implications for subjects with stable COPD.

[1]  A. Schols.  Pulmonary cachexia. , 2002, International journal of cardiology.

[2]  N. Chavannes,et al.  Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum. , 2002, American journal of respiratory and critical care medicine.

[3]  L. Muglia,et al.  COX-2 inhibition attenuates anorexia during systemic inflammation without impairing cytokine production. , 2002, American journal of physiology. Endocrinology and metabolism.

[4]  T. Seemungal,et al.  Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels , 2000, Thrombosis and Haemostasis.

[5]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[6]  Douglas G Altman,et al.  Meta‐analysis combining parallel and cross‐over clinical trials. I: Continuous outcomes , 2002, Statistics in medicine.

[7]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[8]  J. Hogg,et al.  Interaction of alveolar macrophages and airway epithelial cells following exposure to particulate matter produces mediators that stimulate the bone marrow. , 2002, American journal of respiratory cell and molecular biology.

[9]  L. Raisz.  Physiology and pathophysiology of bone remodeling. , 1999, Clinical chemistry.

[10]  H. Saito,et al.  Circulating leptin in patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[11]  R. Rogers,et al.  Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients. , 1996, American journal of respiratory and critical care medicine.

[12]  D. Biskobing.  COPD and osteoporosis. , 2002, Chest.

[13]  A. Ionescu,et al.  Inflammatory response and body composition in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[14]  J. Manson,et al.  Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study. , 2002, JAMA.

[15]  B. Hedblad,et al.  Lung Function and Cardiovascular Risk: Relationship With Inflammation-Sensitive Plasma Proteins , 2002, Circulation.

[16]  D. Mannino,et al.  Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. , 2003, The American journal of medicine.

[17]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[18]  J. Mege,et al.  Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. , 1994, American journal of respiratory and critical care medicine.

[19]  B. Nordestgaard,et al.  Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[20]  W. Bailey,et al.  Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. , 1995, JAMA.

[21]  H. Saito,et al.  The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[22]  P. Ridker,et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.

[23]  S. Basili,et al.  Hypercoagulability State in Patients with Chronic Obstructive Pulmonary Disease , 1994, Thrombosis and Haemostasis.

[24]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[25]  A. James,et al.  Associations between white blood cell count, lung function, respiratory illness and mortality: the Busselton Health Study. , 1999, The European respiratory journal.

[26]  R Peto,et al.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. , 1998, JAMA.

[27]  M. Yeung,et al.  Leukocyte count, smoking, and lung function. , 1984, The American journal of medicine.

[28]  M. Lebowitz,et al.  Death certificate reporting of confirmed airways obstructive disease. , 1991, American journal of epidemiology.

[29]  X. Busquets,et al.  Systemic effects of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[30]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[31]  D. Strachan,et al.  C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. , 2000, European heart journal.

[32]  E. Wouters,et al.  Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. , 1996, Thorax.

[33]  J. Hogg,et al.  The human bone marrow response to acute air pollution caused by forest fires. , 2000, American journal of respiratory and critical care medicine.

[34]  K. Nishigaki,et al.  An increase of soluble Fas, an inhibitor of apoptosis, associated with progression of COPD. , 1998, Respiratory medicine.

[35]  V. Salomaa,et al.  Symptoms of chronic bronchitis, haemostatic factors, and coronary heart disease risk. , 1999, Atherosclerosis.

[36]  M. Di Napoli,et al.  Prognostic Influence of Increased C-Reactive Protein and Fibrinogen Levels in Ischemic Stroke , 2001, Stroke.

[37]  R. Wyatt,et al.  Effects of smoking on inflammatory mediators and their relationship to pulmonary dysfunction. , 1986, European journal of respiratory diseases. Supplement.

[38]  A. Hansell,et al.  What do chronic obstructive pulmonary disease patients die from? Amultiple cause coding analysis , 2003, European Respiratory Journal.

[39]  A. Siegelaub,et al.  Lung function and risk of myocardial infarction and sudden cardiac death. , 1976, The New England journal of medicine.

[40]  W Winkelstein,et al.  Pulmonary function is a long-term predictor of mortality in the general population: 29-year follow-up of the Buffalo Health Study. , 2000, Chest.

[41]  E. Wouters,et al.  Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations , 2001, Thorax.

[42]  S T Holgate,et al.  Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers. , 1999, American journal of respiratory and critical care medicine.

[43]  J. Hogg,et al.  Cytokines involved in the systemic inflammatory response induced by exposure to particulate matter air pollutants (PM(10)). , 2001, American journal of respiratory and critical care medicine.

[44]  V M Hawthorne,et al.  Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study , 1996, BMJ.

[45]  H. Saito,et al.  The Relationship between Chronic Hypoxemia and Activation of the Tumor Necrosis Factor- α System in Patients with Chronic Obstructive Pulmonary Disease , 2000 .

[46]  D. Sin,et al.  Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. , 2003, Circulation.

[47]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[48]  A. Siegbahn,et al.  Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.

[49]  S. Humphries,et al.  Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.